Literature DB >> 10824045

Progressive supranuclear palsy.

H U Rehman1.   

Abstract

Progressive supranuclear palsy (PSP) or Steele-Richardson-Olszewski syndrome is a neurodegenerative disease of middle and late age. It is under-diagnosed not only by general physicians but also by neurologists. The cause of PSP is not known. Exposure to toxins and viruses has been proposed in the aetiology of PSP without any concrete evidence. The features of PSP resemble those of Parkinson's disease and the two diseases are often confused. Corticobasal degeneration and multisystem atrophy are other differential diagnoses. Despite certain common features with Parkinson's disease, corticobasal degeneration, and mutisystem atrophy, there are important differences that help to differentiate it from these disorders.

Entities:  

Mesh:

Year:  2000        PMID: 10824045      PMCID: PMC1741619          DOI: 10.1136/pmj.76.896.333

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  50 in total

1.  Brain amino acids and glutathione in progressive supranuclear palsy.

Authors:  T L Perry; S Hansen; K Jones
Journal:  Neurology       Date:  1988-06       Impact factor: 9.910

2.  Prevalence and natural history of progressive supranuclear palsy.

Authors:  L I Golbe; P H Davis; B S Schoenberg; R C Duvoisin
Journal:  Neurology       Date:  1988-07       Impact factor: 9.910

3.  Decrease of serotonin-S2 receptors in temporal cortex of patients with Parkinson's disease and progressive supranuclear palsy.

Authors:  J M Maloteaux; E C Laterre; P M Laduron; F Javoy-Agid; Y Agid
Journal:  Mov Disord       Date:  1988       Impact factor: 10.338

4.  Dopaminergic and cholinergic lesions in progressive supranuclear palsy.

Authors:  M Ruberg; F Javoy-Agid; E Hirsch; B Scatton; R LHeureux; J J Hauw; C Duyckaerts; F Gray; A Morel-Maroger; A Rascol
Journal:  Ann Neurol       Date:  1985-11       Impact factor: 10.422

5.  [Steele-Richardson-Olszewski disease without ophthalmoplegia. 6 clinico-anatomic cases].

Authors:  F Dubas; F Gray; R Escourolle
Journal:  Rev Neurol (Paris)       Date:  1983       Impact factor: 2.607

6.  Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers.

Authors:  S J Kish; L J Chang; L Mirchandani; K Shannak; O Hornykiewicz
Journal:  Ann Neurol       Date:  1985-11       Impact factor: 10.422

7.  Progressive supranuclear palsy: anatomoclinical and biochemical considerations.

Authors:  Y Agid; F Javoy-Agid; M Ruberg; B Pillon; B Dubois; C Duyckaerts; J J Hauw; J C Baron; B Scatton
Journal:  Adv Neurol       Date:  1987

8.  Risk factors for progressive supranuclear palsy.

Authors:  P H Davis; L I Golbe; R C Duvoisin; B S Schoenberg
Journal:  Neurology       Date:  1988-10       Impact factor: 9.910

9.  Diffuse Lewy body disease presenting with supranuclear gaze palsy, parkinsonism, and dementia: a case report.

Authors:  V M de Bruin; A J Lees; S E Daniel
Journal:  Mov Disord       Date:  1992-10       Impact factor: 10.338

10.  The ocular motor defects in progressive supranuclear palsy.

Authors:  B T Troost; R B Daroff
Journal:  Ann Neurol       Date:  1977-11       Impact factor: 10.422

View more
  5 in total

1.  Diffusion tensor imaging and voxel based morphometry study in early progressive supranuclear palsy.

Authors:  A Padovani; B Borroni; S M Brambati; C Agosti; M Broli; R Alonso; P Scifo; G Bellelli; A Alberici; R Gasparotti; D Perani
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-11-23       Impact factor: 10.154

2.  Brain alterations and mini-mental state examination in patients with progressive supranuclear palsy: voxel-based investigations using f-fluorodeoxyglucose positron emission tomography and magnetic resonance imaging.

Authors:  Ryuichi Takahashi; Kazunari Ishii; Tatsuya Kakigi; Kazumasa Yokoyama; Etsuro Mori; Takamichi Murakami
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2011-11-09

Review 3.  Neurodegenerative diseases: an overview of environmental risk factors.

Authors:  Rebecca C Brown; Alan H Lockwood; Babasaheb R Sonawane
Journal:  Environ Health Perspect       Date:  2005-09       Impact factor: 9.031

4.  Efficacy of Āyurvedic treatment using Pañcakarma combined with balance exercises for disability and balance in progressive supranuclear palsy.

Authors:  Nitin Jindal; Manoj K Shamkuwar; Jaskirat Kaur; Sadhan Berry
Journal:  Anc Sci Life       Date:  2012-07

Review 5.  Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care.

Authors:  Brent Bluett; Alexander Y Pantelyat; Irene Litvan; Farwa Ali; Diana Apetauerova; Danny Bega; Lisa Bloom; James Bower; Adam L Boxer; Marian L Dale; Rohit Dhall; Antoine Duquette; Hubert H Fernandez; Jori E Fleisher; Murray Grossman; Michael Howell; Diana R Kerwin; Julie Leegwater-Kim; Christiane Lepage; Peter Alexander Ljubenkov; Martina Mancini; Nikolaus R McFarland; Paolo Moretti; Erica Myrick; Pritika Patel; Laura S Plummer; Federico Rodriguez-Porcel; Julio Rojas; Christos Sidiropoulos; Miriam Sklerov; Leonard L Sokol; Paul J Tuite; Lawren VandeVrede; Jennifer Wilhelm; Anne-Marie A Wills; Tao Xie; Lawrence I Golbe
Journal:  Front Neurol       Date:  2021-07-01       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.